Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 3Phase 1 3Phase 2/3 2Phase NA 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Breast 1

Conditions

Hodgkin Disease 2Breast Neoplasms 1

Interventions

Carboplatin 127pembrolizumab 123Cisplatin 112Paclitaxel 102Gemcitabine 83Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 69Dexamethasone 59Cyclophosphamide 59Pemetrexed 54Bevacizumab 54Doxorubicin 52durvalumab 51Radiotherapy 49Capecitabine 48Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 39Etoposide 38atezolizumab 35Nivolumab 35Letrozole 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × pegfilgrastim × 90 days × Clear all
NCT04685616 2026-06-02

RADAR

University College, London

Phase 3 Recruiting
1,042 enrolled
Lymphoid

Hodgkin Disease

NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
994 enrolled 11 charts 1 FDA
Lymphoid

Hodgkin Disease

NCT00433420 2026-04-30

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Phase 3 Active not recruiting
2,000 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡